ExQor Technologies Announces Advancement Toward Clinical Trials for Brain Regenerative Medicine Platform to Treat Alzheimer's Disease

Contributed by: PR Newswire

Tags

ExQor-Alzheimer

More Like This

PR Newswire associated0

ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases

PR Newswire associated0

QuantalX Neuroscience Announces CE MDR Approval, Making Brain Health Assessment Available in the EU

PR Newswire associated0

S&E bio Receives Korea's First Approval for Exosome-Based Therapy Clinical Trial

PR Newswire associated0

QuantalX Secures FDA Clearance for its breakthrough Delphi stimulator, advancing direct brain health diagnosis at the point of care

Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients

ONWARD Medical Builds Commercial Momentum for the ARC-EX System and Reinforces its Brain-Computer Interface Leadership in Q1 2025

MULTI-MILLION POUND BOOST FOR RESEARCH PROJECTS AIMED AT DEVELOPING NEW TESTS, TREATMENTS AND DEVICES FOR NEURODEGENERATIVE DISEASES

PR Newswire associated0

Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease.